Search

The bears sure enjoyed a rare day in the sun on Monday. The Dow had its worst day of the year, down more than 3%. Pessimists haven’t loved life like that since March of 2020.

Two days into 2022 and we’re seeing another round of selling in growth names, especially software, fintech, medical devices and e-commerce. Many names are retesting their November and/or December lows. We have seen a few names crack their 200-day lines, while a few others have begun to rebound intra-day.

In two days, the S&P 500 has set two new all-time highs. Last year’s momentum is spilling over so far. But will it last?

The market started out lower this morning after a worse-than-expected jobs report. As of 11:30 am, the Dow is down just 14 points, but the Nasdaq is off 130 points and growth-oriented indexes are down another 1% to 2%.

It’s a new year, and a new attitude. Investors tend to sober up after weeks of holiday slacking and refocus on the market. What are they saying?

Growth stocks are continuing on their path lower so far today while some cyclical stocks perk up—as of 12:15 EST, the Dow is up 115 points but the Nasdaq is down 155 points and most growth stocks are off much more than that.

Well, the market’s small dose of good action for the second half of December was mauled by the bears this week—all indexes are down at least somewhat, and among growth-oriented titles from a variety of sectors (tech, cybersecurity, solar, software, retail, you name it), it’s been nothing short of a mini-crash, with the Nasdaq down 3.5%, growth-oriented indexes down 5% or more and many individual titles off 15% to 20%.

In late December, prior to the holiday, we published the January edition of the Cabot Turnaround Letter. Our first article, “Top Five Stocks for 2022,” we highlighted Credit Suisse (CS), Dril-Quip (DRQ), Lamb Weston Holdings (LW), Nokia (NOK) and TreeHouse Foods (THS).

Two days into 2022 and we’re seeing another round of selling in growth names, especially software, fintech, medical devices and e-commerce. Many names are retesting their November and/or December lows. We have seen a few names crack their 200-day lines, while a few others have begun to rebound intra-day.

Stocks failed to even bounce today despite all the selling of late. At day’s end, the Dow was off 171 points and the Nasdaq dropped 19 points.

The indexes plummeted on rising rate worries and disappointing Goldman Sachs (GS) earnings. The benchmark 10-year Treasury rate soared to 1.85 on Tuesday. That’s the highest level since the pandemic began and up from 1.34% as recently as last month.

The market is getting hit again today, though some stocks are trying to put up a fight. As of 12 am EST, the Dow is down 80 points and the Nasdaq is off another 134 points.

So far, 2022 is playing out as expected. But of course, this is only the eighth trading day of the year.

Stocks started off on a positive note today, but once again sold off sharply into the close. At day’s end, the Dow was down another 313 points, and the Nasdaq was off 186 points.

The S&P 600 Index just made another run but called it quits at 990 and has turned south.

This portfolio stock shares are down 7% as investors worry about a potential pharmaceutical competitor.

A high percentage of stocks that I follow are exhibiting bullish price charts right now. Obviously, you already knew that the stock market has been acting well. I simply want to reiterate that the recent bullishness appears to be sustainable. Enjoy!

Not a lot has changed since last week’s issue—overall, the cannabis sector remains in a correction—but there are a few stocks worthy of an update.

One of the portfolio stocks reported third-quarter results.

Here we are within weeks of the end of year and the end of a decade. It is approaching the 11th year of the recovery and bull market. The S&P 500 is up 25% in 2019 and very near the all-time high. Where do we go from here?